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Abstract
Background: Polymorphisms in and around the CTLA-4 gene have previously been associated to
T1D and AITD in several populations. One such single nucleotide polymorphism (SNP), CT60, has
been reported to affect the expression level ratio of the soluble (sCTLA-4) to full length CTLA-4
(flCTLA-4) isoforms. The aims of our study were to replicate the association previously published
by Ueda et al. of polymorphisms in the CTLA-4 region to T1D and AITD and to determine whether
the CT60 polymorphism affects the expression level ratio of sCTLA-4/flCTLA-4 in our population.
Methods: Three SNPs were genotyped in 253 cases (104 AITD cases and 149 T1D cases) and 865
ethnically matched controls. Blood from 23 healthy individuals was used to quantify mRNA
expression of CTLA-4 isoforms in CD4+ cells using real-time PCR. Serum from 102 cases and 59
healthy individuals was used to determine the level of sCTLA-4 protein.
Results: Here we show association of the MH30, CT60 and JO31 polymorphisms to T1D and
AITD in northern Sweden. We also observed a higher frequency of the CT60 disease susceptible
allele in our controls compared to the British, Italian and Dutch populations, which might
contribute to the high frequency of T1D in Sweden. In contrast to previously published findings,
however, we were unable to find differences in the sCTLA-4/flCTLA-4 expression ratio based on
the CT60 genotype in 23 healthy volunteers, also from northern Sweden. Analysis of sCTLA-4
protein levels in serum showed no correlation between sCTLA-4 protein levels and disease status
or CT60 genotype.
Conclusion: Association was found between T1D/AITD and all three polymorphisms investigated.
However, in contrast to previous investigations, sCTLA-4 RNA and protein expression levels did
not differ based on CT60 genotype. Our results do not rule out the CT60 SNP as an important
polymorphism in the development of T1D or AITD, but suggest that further investigations are
necessary to elucidate the effect of the CTLA-4 region on the development of T1D and AITD.
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Autoimmune thyroid disease (AITD) and type 1 diabetes
mellitus (T1D) are autoimmune disorders under complex
genetic control that develop through a process mediated
by T lymphocytes [1]. Association between T1D and AITD
is well known, and these diseases frequently cluster within
the same family and in the same individual [2] indicating
common genetic causes [1,3,4]. Risk of both T1D and
AITD has been linked to the cytotoxic T-lymphocyte asso-
ciated antigen-4 (CTLA-4) region on chromosome 2q33
in many populations including the Swedish, Italian and
Finnish [5-7]. Fine mapping in and around the CTLA-4
gene performed by Ueda et al. [8] narrowed down the
region of association to single nucleotide polymorphisms
(SNPs) 3' of the CTLA-4 and 5' of the inducible co-stimu-
lator (ICOS) genes. The CT60 polymorphism
(rs30807243), located 3' to the known polyadenylation
site of CTLA-4, showed the highest association to autoim-
mune disease. Investigation of full-length CTLA-4
(flCTLA-4) and soluble CTLA-4 (sCTLA-4) [8,9] expres-
sion based on the CT60 genotype revealed a lower expres-
sion of sCTLA-4 in individuals homozygous for the G
allele in the UK population [8]. In line with this notion we
previously analyzed a large pedigree from northern Swe-
den in which multiple individuals suffered T1D and
AITD. Applying a model in which all T1D and AITD
patients were considered affected, evidence in form of
linkage to the MHC and the CTLA-4 loci was obtained [5].
Based on this background, we set out to investigate the
previously published[8] association of three polymor-
phisms in the CTLA-4 region to T1D and AITD in the pop-
ulation of northern Sweden and subsequently investigate




Three SNPs adjacent to the CTLA-4 gene, MH30
(rs231806), CT60 (rs30807243) and JO31 (rs11571302)
were genotyped in 1118 subjects from northern Sweden
(104 patients with AITD, 149 patients with T1D and 865
matched controls). Cases were identified through an
autoimmune disease register at Sunderby hospital in
northern Sweden. Healthy volunteers from northern Swe-
den were used as ethnically matched controls. The study
was carried out with the approval of the regional ethical
review board and informed consent was obtained from all
participants.
Blood from 23 healthy individuals (relatives to cases in
the Sunderby autoimmune disease register) was used to
measure the expression of flCTLA-4, sCTLA-4 and ICOS.
Serum from 59 healthy individuals, 43 individuals with
AITD, 46 individuals with T1D and 13 individuals with
both AITD and T1D was used to determine the level of
sCTLA-4 protein.
DNA extraction
Genomic DNA from cases was extracted from mouth
swabs. Detailed instructions for mouth swab sampling
were sent to each individual with a kit containing all nec-
essary reagents. Mouth swabbing was performed by rub-
bing the inside of the cheek with a small brush for
approximately 30 sec. The brush was then placed in 600
μl 50 mM NaOH and returned to the laboratory by stand-
ard mail. Mouth swabs were vortexed shortly before incu-
bation at 95°C for 10 min. After incubation the mouth
swabs were vortexed again, the brush was removed from
each tube, 50 μl 1 M Tris-HCl (pH 8.0) was added to each
tube and the tubes were stored at 4°C.
Genomic DNA from controls was extracted from whole
blood using standard phenol-chisam methods.
Genotyping of polymorphisms in close proximity to 
CTLA-4
The three SNPs of interest were genotyped using TaqMan
Assay-by-Design (Applied Biosystems, Foster City, CA,
USA). Assays were performed according to the manufac-
turer's instructions. MH30 is located 5' of the CTLA-4 tran-
script and both CT60 and JO31 are located 3' of the CTLA-
4 transcript. Genotypes were analyzed using the allelic dis-
crimination function of the TaqMan 7900 HT Fast Real-
Time PCR system (Applied Biosystems, Foster City, CA,
USA). 8% of the total samples were run in duplicate for
each SNP, and 100% concordance was observed between
duplicates. A genotyping success rate from 89.9% to
99.5% (Table 1) was obtained for the SNPs under investi-
gation.
CD4+ Cell Sorting
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from heparinized whole blood by density gradient
centrifugation using Vacutainer CPT tubes (BD Bio-
sciences, NJ, USA). CD4+ T cells were purified by MACS
cell separation using biotin-conjugated mouse anti-
human CD4+ monoclonal antibody (clone: RPA-T4, BD
Biosciences, NJ, USA), streptavidin microbeads and MACS
MS columns (MACS, Miltenyi Biotec, Germany). Average
purity was found to be 97.7% by FACS analysis (FACSCal-
ibur, BD Biosciences, NJ, USA). Streptavidin-PE antibody
(BD Biosciences, NJ, USA) was used for FACS analysis.
RNA and cDNA preparation
RNA was prepared using RNeasy Mini Kit (Qiagen, Ger-
many) and dissolved in 40 μl of RNase-free water fol-
lowed by treatment with DNase I (Ambion, Austin, TX,
USA). RNA concentrations were measured (ND-1000
spectrophotometer, Nanodrop Technologies, Delaware,Page 2 of 8
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using the Reverse Transcription Reagents (TaqMan) pur-
chased from Applied Biosystems (Applied Biosystems,
Foster City, CA, USA). Each preparation step was per-
formed according to the manufacturer's instructions.
Gene expression
Real-time quantitative (TaqMan) PCR was performed,
employing the ribosomal protein L13 (RPL13) as a con-
trol transcript, to investigate expression of sCTLA-4,
flCTLA-4 and ICOS. Primers and probes used to measure
the RNA expression were:
flCTLA-4: forward primer 5'-GAACCCAGATTTATG-
TAATTGATCCA-3', reverse primer 5'-CCGAACTAACT-
GCTGCAAGGA-3', probe 5'-(FAM)-
CGTGCCCAGATTCTGACTTCCTCCTCT-(TAMRA)-3'.
sCTLA-4: forward primer 5'-CATCTGCAAGGTGGAGCT-
CAT-3', reverse primer 5'-GGCTTCTTTTCTTTAGCAATTA-
CATAAATC-3', probe 5'-(FAM)-
ACCGCCATACTACCTGGGCATAGGCA-(TAMRA)-3'.
ICOS: forward primer 5'-TGTTTCT GGCAAACAT-
GAAGTCA-3', reverse primer 5'-GCAGAACCATTGATT-
TCTCCTGTTA-3', probe 5'-(VIC)-
CCTCTGGTATTTCTTTCTCTTCTGCTTGCGC-(TAMRA)-
3'. RPL13: forward primer 5'-CCGCTCTGGACCGTCT-
CAA-3', reverse primer 5'-CCTGGTACTTC-
CAGCCAACCT-3', probe 5'-(VIC)-
TGACGGCATCCCACCGCCCT-(TAMRA)-3'. Primers
were designed using Primer Express (Applied Biosystems,
Foster City, CA, USA) and purchased from Applied Biosys-
tems.
Relative expression of the transcripts was measured in the
TaqMan 7900 HT Fast Real-Time PCR system (Applied
Biosystems, Foster City, CA, USA) and determined by rel-
ative RNA quantification using the comparative Ct
method as described by Livak and Schmittgen [10].
Briefly, the amount of target transcript normalized to an
endogenous control gene and relative to a calibrator sam-
ple (total RNA prepared from PBMCs) is given by the for-
mula: 2-ΔΔCt, where ΔΔCt = (Cttarget-Ctendogenous control)
sample in study – (Cttarget-Ctendogenous control) calibrator.
Expression levels of each gene were compared on the basis
of the individuals CT60 genotype.
To determine the sCTLA-4/flCTLA-4 mRNA expression,
we used the formula:
2-(Ct(sCTLA-4)-Ct(flCTLA-4)), as per [8].
Table 1: Significant association of MH30, CT60 and JO31 to autoimmune disease in northern Sweden.
MH30 Case (%) Control (%) OR (95%CI) P value
CC 16 (6.7) 108 (13.9)
CG 111 (46.4) 362 (46.6)
GG 112 (46.9) 307 (39.5)
CG vs. CC 2.07 (1.18–3.65) 0.01
GG vs. CC 2.46 (1.40–4.35) 0.002
Multiplicative model 1.40 (1.12–1.75) 0.004
Success rate (%) 94.5 89.9
CT60
AA 15 (6.4) 117 (14.4)
AG 111 (47.2) 394 (48.5)
GG 109 (46.4) 301 (37.1)
AG vs. AA 2.20 (1.23–3.91) 0.008
GG vs. AA 2.83 (1.58–5.05) 5 × 10-4
Multiplicative model 1.50 (1.19–188) 5 × 10-4
Success rate (%) 92.9 93.9
JO31
TT 18 (7.4) 131 (15.2)
GT 116 (47.7) 414 (48.1)
GG 109 (44.9) 316 (36.7)
GT vs. TT 2.04 (1.20–3.48) 0.009
GG vs. TT 2.51 (1.47–4.30) 8 × 10-4
Multiplicative model 1.44 (1.15–1.79) 0.001
Success rate (%) 96.0 99.5
Allelic discrimination was used to genotype MH30 (rs231806), CT60 (rs30807243) and JO31 (rs11571302) in 253 cases and 865 controls from 
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(page number not for citation purposes)
BMC Medical Genetics 2007, 8:3 http://www.biomedcentral.com/1471-2350/8/3Detection of sCTLA-4 serum levels
Sandwich immunoassay for sCTLA-4 was developed in
our laboratory and performed using Gyrolab Bioaffy plat-
form (Gyros AB, Uppsala, Sweden). Briefly, the system
consists of a working station performing all transfers of
liquid from a microtiter plate into a CD microlaboratory,
Gyrolab Bioaffy, and an integrated fluorescence detector
for laser-induced fluorescence (LIF). The CD microlabora-
tory contains 104 identical microstructures, connected in
groups of 8, to generate 104 data points. The microstruc-
tures contain a 15 nl streptavidin column to which
selected capture biotinylated antibodies can be attached
followed by addition of samples and detection antibodies
previously labeled with Alexa Fluor 647 (Molecular
Probes, Eugene, OR, USA) to form a sandwich immu-
noassay. Liquid introduction is facilitated by capillary
force and further movement of liquids within the CD
microlaboratory is driven by centrifugal force when spin-
ning the CD. The detected fluorescence is compared with
a standard curve processed in an identical fashion.
Patient serum samples stored at -20°C were slowly
thawed on ice. The samples were then vortexed and cen-
trifuged for 15 minutes at 4000 rpm and 8°C. Each sam-
ple was then diluted 1:10 (1 μl + 9 μl buffer) in microtiter
platesin duplicate. Biotinylated anti-human CD152
(AS33-B; Antibody Solutions, Palo Alto, CA) was used as
a capture antibody followed by a complementary anti-
human CD152 antibody (BNI.3; BD PharMingen, San
Diego, CA) previously labeled with Alexa Fluor 647
(Molecular Probes, Eugene, OR, USA) following the man-
ufacturer instructions. These two matching anti-human
CD152 antibodies were previously shown to be suitable
for sandwich immunoassay [11]. After each addition of
reagents or samples to the microstructure, the streptavidin
columns were washed repeatedly using 0.01 M phosphate
buffered saline, pH 7.2, containing 0.01% Tween-20
(PBS-T). CTLA4-Ig protein (Ancell, Bayport, MN) was
used to generate an eight point standard curve (10 –
0.0015 ng/ml range) including a blank. sCTLA-4 protein
was quantified in duplicate and calculated using Gyrolab
Evaluator software(Gyros AB, Uppsala Sweden). The sen-
sitivity limit for this assay was 0.062 ng/ml on average.
Statistical analysis
Association analysis was performed by means of logistic
regression. Genotype-based odds ratios (ORs) were calcu-
lated using individuals homozygous for the non-suscepti-
ble allele as the reference. Allele specific ORs were
calculated under the assumption of a multiplicative risk
model. The logistic regression was carried out in SPSS 14.0
and P-values were calculated using the Wald test. Estima-
tion of linkage disequilibrium (LD) was performed in
Haploview [12]. Markers were tested for deviation from
Hardy-Weinberg equilibrium by χ2 goodness-of-fit tests in
the control group. Differences in the sCTLA-4/flCTLA-4
mRNA expression between the CT60 genotype groups (AA
vs. AG and AA vs. GG) were examined by the Wilcoxon
rank sum test.
Results
We genotyped three SNPs in the CTLA-4 region in 253
cases (104 patients with AITD and 149 patients with T1D)
and 865 ethnically matched controls. The investigated
SNPs are in strong LD with each other (JO31-MH30 D'=
0.993 r2 = 0.887, JO31-CT60 D'= 0.988 r2 = 0.94, MH30-
CT60 D'= 0.996 r2 = 0.93). Distributions of alleles in the
investigated SNPs did not deviate significantly from
Hardy-Weinberg equilibrium.
For the three associated SNPs, the recessive mode of inher-
itance could be rejected since heterozygous individuals
clearly have a greater risk compared to non-carriers (P <
0.05 for each SNP, Table 1). However, we did not observe
any increased risk in homozygous individuals compared
to heterozygous carriers (MH30 p = 0.26, CT60 p = 0.11
and JO31 p = 0.17) allowing for both dominant and mul-
tiplicative modes of inheritance in our AITD/T1D case-
control material.
Next we analyzed the mRNA expression of flCTLA-4,
sCTLA-4 and ICOS based on the CT60 genotype of 23
healthy individuals. CD4+ T cells were sorted from
PBMCs using MACS cell separation. FACS analysis
revealed an average purity of 97.7%. To account for the
fact that the number of CTLA-4 positive cells varies
between individuals, flCTLA-4 was used to normalise the
sCTLA-4 values, as has been done previously [8]. No sig-
nificant difference in the ratio of sCTLA-4 to flCTLA-4
mRNA expression based on the CT60 genotype could be
detected (Figure 1). Both sCTLA-4 and flCTLA-4 mRNA
expression, according to CT60 genotype, is given in Figure
2. ICOS expression analysis was also performed in the
same individuals and no significant difference based on
the CT60 genotype could be found (Figure 2). Analysis of
serum sCTLA-4 protein levels in healthy individuals, AITD
patients, T1D patients and individuals with both diseases
revealed no significant differences when comparing dis-
ease status (Figure 3A). Subdividing the healthy individu-
als based on their CT60 genotype also resulted in no
significant differences (Figure 3B).
Discussion
CTLA-4 is an important negative regulator of T cell activa-
tion and we have found association between T1D/AITD
and polymorphisms in close proximity to CTLA-4 using
253 cases (104 patients with AITD and 149 patients with
T1D) and 865 ethnically matched controls from northern
Sweden.Page 4 of 8
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MH30*G, CT60*G and JO31*G are significantly higher
in cases than controls is consistent with studies performed
in other populations including the British [8,13], Italian
[14], Dutch [15] and Japanese [16,17]. The high fre-
quency of the CT60 disease susceptible G allele in our
control material (61.3%) compared to the British
(53.2%), Italian (48%) and Dutch (53.3%) control mate-
rials [8,14,15] might contribute to the high incidence of
T1D in Sweden, which has the third highest T1D inci-
dence in the world [18,19]. In fact, the frequency of the
CT60*G allele was higher in our controls compared to the
Italian Graves' disease cases (56%) and Dutch T1D cases
(60%), and similar to the British Graves' disease cases
(63.4%) [8,14,15]. In agreement with this, the frequency
of the MH30*G allele was also higher in our controls
(62.8%) compared to T1D cases in the Dutch population
(60.6%) [15], and similar to Graves' disease cases in the
British population (64.6%) [8]. For JO31, the frequency
of the G allele in our controls (60.7%) was similar to Brit-
ish Graves' disease cases (61%) [8].
We have developed a sensitive sandwich immunoassay
using the Gyrolab Bioaffy platform technology to detect
and quantify sCTLA4 in serum samples. This technique
has several advantages compared with standard ELISA
assay. First, the standardization of liquid input into the
detection system reduced dramatically variations within
samples as well as intra- and infra-assay variation. Further,
the possibility to visualize binding peaks as a histogram
from the Gyros platform improved the optimisation of
the assay and decreases background levels and finally the
Gyros matrix technology and the particular sensitive lumi-
nescence read-out has significantly improved the detec-
tion limit of the assay compared to commercial ELISA kit
(data not shown).
Analysis of sCTLA-4 and flCTLA-4 mRNA expression was
performed and contrary to a previous report [8] we could
not detect any significant difference in the ratio of sCTLA-
4 to flCTLA-4 mRNA expression based on the CT60 geno-
type. Atabani et al. found lower sCTLA-4 to flCTLA-4
mRNA expression when comparing the CT60 GG and AA
Expression of the human sCTLA-4/flCTLA-4 mRNA ratio does not correlate with CT60 genotypeFigure 1
Expression of the human sCTLA-4/flCTLA-4 mRNA ratio does not correlate with CT60 genotype. Expression of 
each CTLA-4 isoform was measured by real-time quantitative PCR of RNA purified from CD4+ T cells of 23 healthy volun-
teers. Lines represent average values within each CT60 genotype group.Page 5 of 8
(page number not for citation purposes)
BMC Medical Genetics 2007, 8:3 http://www.biomedcentral.com/1471-2350/8/3genotypes, however this analysis was performed in the
smaller CD4+ CD25+ T cell subset [20]. No significant dif-
ference was found when analysing ICOS mRNA expres-
sion based on CT60 genotype. Our results are supported
by data from Anjos et al. [21], who also found no effect of
the CT60 polymorphism on the expression of sCTLA-4,
flCTLA-4 or ICOS when looking at RNA extracted directly
from PBMCs rather than isolated CD4+ T cells. The studies
mentioned above have used different populations of cells
to measure mRNA expression of CTLA-4 isoforms. This
might influence the result, since CD4+ CD25+ T cells con-
stitutively express CTLA-4, while CD4+ CD25- T cells have
a much lower expression of CTLA-4 [20]. Besides the dif-
ference in expression between CD4+ CD25+ and
CD4+CD25- cells, CTLA-4 is expressed by a variety of other
cell types including activated CD8+ T cells, activated B cells
and both single and double positive thymocytes [22,23].
Analysis of serum sCTLA-4 protein levels revealed no dif-
ference in sCTLA-4 protein expression based on disease
status or CT60 genotype. Taken together, these results sug-
gest that the level of serum sCTLA-4 protein is not corre-
lated with disease status or CT60 genotype. Measurement
of sCTLA-4 protein levels in serum performed by Purohit
et al. [24] revealed slightly elevated sCTLA-4 protein levels
in T1D patients compared to controls. When grouping the
individuals according to their CT60 genotype no differ-
ence in serum sCTLA-4 protein levels was found, in agree-
ment with our findings. Oaks et al. [11] found higher
levels of sCTLA-4 in serum from AITD patients compared
Expression of human flCTLA-4, sCTLA-4 and ICOS mRNA does not correlate with CT60 genotypeFigure 2
Expression of human flCTLA-4, sCTLA-4 and ICOS mRNA does not correlate with CT60 genotype. Expression 
was measured by real-time quantitative PCR of RNA purified from CD4+ T cells of 23 healthy volunteers. RPL13 was used as an 
endogenous control. Error bars represent SD. Black, white and grey bars represent flCTLA-4, sCTLA-4 and ICOS mRNA 
expression respectively.Page 6 of 8
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smaller than ours, with only 20 affected individuals and
30 healthy controls. They did not look at the effect of
CT60 genotype on serum sCTLA-4 levels.
Conclusion
In conclusion, we have shown association of three previ-
ously described polymorphisms (MH30, CT60, and
JO31) in the CTLA-4 gene region to T1D and AITD in
northern Sweden. The frequency of the CT60 disease sus-
ceptible G allele was considerably higher in our popula-
tion compared to the British, Italian and Dutch
populations. However, in contrast to previously pub-
lished data [8], we could not find any correlation between
CT60 genotype and the expression of CTLA-4 isoforms,
despite using a larger sample size. Analysis of sCTLA-4
protein levels in serum revealed no correlation to either
disease status or CT60 genotype. While these data do not
rule out CT60 as an important polymorphism in the
development of T1D and AITD, they underline the need
for further studies in order to elucidate the effect of the
CTLA-4 region on the development of T1D and AITD.
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